<DOC>
	<DOCNO>NCT00804921</DOCNO>
	<brief_summary>Purpose : To evaluate effect anterior chamber paracentesis , brimonidine oral acetazolamide reduce intra-ocular pressure ( IOP ) variation intravitreal bevacizumab injection ( IVBV ) . Methods : 47 patient schedule IVBV ( 1.5 mg / 0.06 ml ) randomly assign pre-treatment 1 hour IVBV either 250 mg oral acetazolamide ( DIA , 9 eye ) , anterior chamber paracentesis immediate IVBV ( PAR , 15 eye ) , topic brimonidine tartarate 1 hour IVBV ( BRI , 14 eye ) , pre-treatment IBVB ( CTR , 9 eye ) . IOP measure 90 minute injection ( baseline ) , injection , 3 , 10 , 20 30 minute procedure .</brief_summary>
	<brief_title>Effectiveness Oral Acetazolamide , Brimonidine Tartarate , Anterior Chamber Paracentesis Intraocular Pressure ( IOP ) After Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>macular edema pulmonary chronic problem chronic renal failure intraocular inflammation drug alcohol addiction</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>intra-ocular pressure</keyword>
	<keyword>acetazolamide</keyword>
	<keyword>anterior chamber paracentesis</keyword>
	<keyword>brimonidine</keyword>
	<keyword>macular edema secondary diabetic retinopathy macular degeneration</keyword>
</DOC>